GO
Loading...

United Therapeutics Corp

More

  • Shares of United Therapeutics closed up $26.14 at $117.83 on the Nasdaq, boosting the company's market value by about $1.24 billion to $5.57 billion.

  • In afternoon trading, United Therapeutics' shares were up $24.56, or 26.8 percent, at $116.25, after earlier rising as much as 28.7 percent to a record $118.00.

  • Cramer’s homework uncovers intriguing stock Friday, 10 Jan 2014 | 6:52 PM ET

    Sometimes Cramer tells a caller that he needs to do homework before he can make a decision on a stock. He's not kidding.

  • Midday Movers: Apple, Target, Micron & More Monday, 23 Dec 2013 | 12:35 PM ET

    Some of Monday's midday movers:

  • Lightning Round: Pier 1, Green Mountain & More Monday, 2 Dec 2013 | 6:48 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Lightning Round: Facebook, Deere & More Wednesday, 9 Oct 2013 | 6:40 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Lightning Round: Yahoo!, AMD & More Wednesday, 2 Oct 2013 | 6:41 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Predictions for FDA Drug Approvals Tuesday, 12 Mar 2013 | 12:13 PM ET

    TheStreet.com reports its investor predictions for FDA drug approvals in 2013: Bad news for Arena Pharmaceuticals, Delcath Systems and Aveo Pharmaceuticals, but Sarepta Therapeutics and Ziopharm are among the winners.

  • FDA declines United's drug application Tuesday, 23 Oct 2012 | 6:16 PM ET

    SILVER SPRING, Md.-- United Therapeutics Corp. said Tuesday that the U.S. Food and Drug Administration declined its application for an extended-release tablet version of its pulmonary arterial hypertension drug treprostinil.

  • How 3D Printers Are Reshaping Medicine Wednesday, 10 Oct 2012 | 12:25 PM ET
    Bioprinting

    Printing off a kidney or another human organ may sound like something out of science fiction, but with advancements in 3D printing technology, the idea may not be so far-fetched.

  • Cramer makes the call on viewers' favorite stocks.

  • Stocks on the Move Now: Michael Kors Skyrockets Tuesday, 14 Feb 2012 | 12:53 PM ET
    By The Numbers | Stocks on the Move Now

    Shares of Michael Kors spiked Tuesday, as the luxury retailer reported a 47 percent increase in fiscal third-quarter earnings. 

  • In breaking news CNBC's Scott Cohn says a former Nasdaq employee has pled guilty to securities fraud for insider trading.

  • S&P May Reach 1400-1430 by End of May: Strategist Tuesday, 10 May 2011 | 11:09 AM ET

    The S&P may reach the 1,400 to 1,430 level between now and the end of May, said Michael McGervey, president of McGervey Wealth Management. He explained his thinking to CNBC.

  • Exclusive Picks From Street’s Top Biotech Analyst Friday, 19 Nov 2010 | 5:24 PM ET

    It appears the biotech news flow is heating up.  But should you get in before year's end? 

  • Sector Trade: Biotech Monday, 28 Sep 2009 | 5:32 PM ET

    Investors are placing their bets on the next M&A deal in biotech. Where should you be looking?

  • Dendreon Makes The List...Again Friday, 25 Sep 2009 | 12:44 PM ET

    2,226 percent. That is the astronomical increase in shares of baby biopharma Vanda so far this year. And it's the prime historical example of "Biotech Takeouts and Breakouts" Bernstein's Geoffrey Porges uses in a sequel research note to clients he put out today.

  • Following are the day’s biggest winners and losers. Find out why shares of Las Vegas Sands and Colgate-Palmolive popped while Abercrombie & Fitch and Alcoa dropped.

  • Analyst: Pfizer Should Buy Amgen or Wyeth Friday, 7 Mar 2008 | 10:48 AM ET

    I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...

  • Looking Great For '08: Citi's 58 Top Stock Picks Thursday, 3 Jan 2008 | 2:52 PM ET

    The first days of the New Year bring Citigroup's Citi Investment Research Top Picks: The bank polled each of its fundamental analysts on a single best money-making idea for 2008, with the option of an additional small-cap pick.  Citi says its 2007 list produced an average share price return of 16.7 percent, well ahead of the Standard and Poor's 500 average of 4.2 percent.